Novartis AG

Swiss drugmaker Novartis AG clinched an agreement with England’s state-funded health service to make a cutting-edge cancer therapy available to children with a devastating form of leukemia in the first arrangement of its kind in Europe.

StockMarketNews.Today – Young patients could begin receiving Kymriah, which has a list price of about 282,000 pounds ($363,000), within weeks, England’s National Health Service said in a statement Wednesday. The accord comes just days after a similar therapy, Gilead Sciences Inc.’s Yescarta, was rejected in the U.K. for treatment of a different type of cancer.